Effects of P-cresol, a Uremic Toxin, on Cancer Cells

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2023 Mar 14

PMID 36915599

Authors

Xiaohong Chen

Fangfang Xiang

Xuesen Cao

Jianzhou Zou

Boheng Zhang

Xiaoqiang Ding

Affiliations

Soon will be listed here.

Abstract

Background: Though p-cresol exists at a low concentration in the blood, it accumulates in various organs of uremic patients. Previous research has shown that the p-cresol promoted bladder cancer cell invasion and migration. This study aims to see if p-cresol had similar effects on kidney cancer cells and liver cancer cells.

Methods: For 48 hours, 786-O human renal cancer cells and HepG2 human liver cancer cells were treated with p-cresol at concentrations of 0, 10, 20, 40, and 70 µM. The effects of p-cresol on cell viability, apoptosis, migration, and invasion were then analyzed using the CCK-8, TUNEL, and Transwell migration/invasion assays, respectively.

Results: P-cresol at 0 to 70 µM for 48 hours had no significant toxic effects on 786-O cells or HepG2 cells. We chose 40 µM p-cresol for 48 hours for the following experiment. The viability and proliferation of 786-O cells and HepG2 cells were unaffected after 48 hours of treatment, with 40 µM p-cresol. However, 40 µM p-cresol for 48 hours promoted HepG2 cell migration and invasion but did not have the same effect on the 786-O cell line.

Conclusions: P-cresol may be responsible for HepG2 cells' malignant biological behavior. Because the liver is the primary site of p-cresol metabolism, it is important to study the responses of cancer cells in the liver to p-cresol.

References

Gryp T, Vanholder R, Vaneechoutte M, Glorieux G . p-Cresyl Sulfate. Toxins (Basel). 2017; 9(2). PMC: 5331431. DOI: 10.3390/toxins9020052. View

Lekawanvijit S . Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome. Toxins (Basel). 2018; 10(9). PMC: 6162485. DOI: 10.3390/toxins10090352. View

Fujii H, Goto S, Fukagawa M . Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction. Toxins (Basel). 2018; 10(5). PMC: 5983258. DOI: 10.3390/toxins10050202. View

Lowrance W, Ordonez J, Udaltsova N, Russo P, Go A . CKD and the risk of incident cancer. J Am Soc Nephrol. 2014; 25(10):2327-34. PMC: 4178430. DOI: 10.1681/ASN.2013060604. View

Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E . Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant. 2011; 26(5):1464-7. DOI: 10.1093/ndt/gfr056. View

Andriamihaja M, Lan A, Beaumont M, Audebert M, Wong X, Yamada K . The deleterious metabolic and genotoxic effects of the bacterial metabolite p-cresol on colonic epithelial cells. Free Radic Biol Med. 2015; 85:219-27. DOI: 10.1016/j.freeradbiomed.2015.04.004. View

Lin H, Li Y, Wang C, Chou C, Kuo D, Fang T . Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transplant. 2011; 27(4):1585-90. DOI: 10.1093/ndt/gfr464. View

Tanaka S, Yano S, Sheikh A, Nagai A, Sugimoto T . Effects of uremic toxin p-cresol on proliferation, apoptosis, differentiation, and glucose uptake in 3T3-L1 cells. Artif Organs. 2014; 38(7):566-71. DOI: 10.1111/aor.12252. View

Vanholder R, Glorieux G, De Smet R, Lameire N . New insights in uremic toxins. Kidney Int Suppl. 2003; (84):S6-10. DOI: 10.1046/j.1523-1755.63.s84.43.x. View

10.

Stewart J, Buccianti G, Agodoa L, Gellert R, McCredie M, Lowenfels A . Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol. 2002; 14(1):197-207. DOI: 10.1097/01.asn.0000039608.81046.81. View

11.

Mandayam S, Shahinian V . Are chronic dialysis patients at increased risk for cancer?. J Nephrol. 2008; 21(2):166-74. View

12.

Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R . P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 2006; 22(2):592-6. DOI: 10.1093/ndt/gfl584. View

13.

Shebl F, Warren J, Eggers P, Engels E . Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol. 2012; 13:65. PMC: 3441292. DOI: 10.1186/1471-2369-13-65. View

14.

Lisowska-Myjak B . Uremic toxins and their effects on multiple organ systems. Nephron Clin Pract. 2014; 128(3-4):303-11. DOI: 10.1159/000369817. View

15.

Hsu Y, Huang H, Chang H . The uremic toxin p-cresol promotes the invasion and migration on carcinoma cells via Ras and mTOR signaling. Toxicol In Vitro. 2019; 58:126-131. DOI: 10.1016/j.tiv.2019.03.029. View

16.

Wong G, Hayen A, Chapman J, Webster A, Wang J, Mitchell P . Association of CKD and cancer risk in older people. J Am Soc Nephrol. 2009; 20(6):1341-50. PMC: 2689896. DOI: 10.1681/ASN.2008090998. View

17.

Assem M, Lando M, Grissi M, Kamel S, Massy Z, Chillon J . The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders. Toxins (Basel). 2018; 10(7). PMC: 6071092. DOI: 10.3390/toxins10070303. View

18.

Kjellstrand C . Are malignancies increased in uremia?. Nephron. 1979; 23(4):159-61. DOI: 10.1159/000181627. View

19.

Chien C, Han M, Chiu Y, Wang J, Chu C, Hung C . Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer. 2017; 8(1):9-18. PMC: 5264035. DOI: 10.7150/jca.16550. View

20.

Cohen G . Immune Dysfunction in Uremia 2020. Toxins (Basel). 2020; 12(7). PMC: 7404977. DOI: 10.3390/toxins12070439. View